• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cushing's Syndrome - Pipeline Review, Q4 2010 - Product Image

Cushing's Syndrome - Pipeline Review, Q4 2010

  • ID: 1474228
  • December 2010
  • 33 pages
  • Global Markets Direct

Cushing's Syndrome - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Cushing's Syndrome Pipeline Review, Q4 2010”, provides an overview of the Cushing's Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Cushing's Syndrome , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cushing's Syndrome . “Cushing's Syndrome -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Cushing's Syndrome   .
- A review of the Cushing's Syndrome    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cushing's Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Cushing's Syndrome
Cushing's Syndrome Therapeutics under Development by Companies
Cushing's Syndrome Therapeutics under Investigation by Universities/Institutes
Companies Involved in Cushing's Syndrome Therapeutics Development
Novartis AG
Corcept Therapeutics Incorporated
Samaritan Pharmaceuticals, Inc.
HRA Pharma, SA
Universities/Institutes Involved in Cushing's Syndrome Therapeutics Development
Cushing's Syndrome Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Corlux - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mifedren - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-6300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Cabergoline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cushing's Syndrome - Featured News
Sep 22, 2010: Novartis Announces Phase III Trial Results Of SOM230 In Patients With Cushing's Disease
Jul 01, 2010: Corcept Completes Enrollment In Phase III Cushing's Syndrome Study Of CORLUX
Jun 25, 2010: Corcept Nears Completion Of Enrollment In Phase III Cushing’s Syndrome Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos